Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 69,698 | 67,808 | 75,643 | 85,781 | 93,130 |
| Receivables | 1,603 | 9,581 | 8,536 | 8,906 | 9,010 |
| TOTAL | $73,231 | $80,220 | $88,058 | $96,455 | $107,201 |
| Non-Current Assets | |||||
| PPE Net | 377 | 386 | 448 | 510 | 535 |
| Other Non-Current Assets | 773 | 566 | 1,490 | 1,231 | 1,073 |
| TOTAL | $1,150 | $952 | $1,938 | $1,741 | $1,608 |
| Total Assets | $74,381 | $81,172 | $89,996 | $98,196 | $108,808 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,604 | 1,799 | 2,636 | 1,820 | 1,678 |
| Accrued Expenses | 7,104 | 7,897 | 8,054 | 8,002 | 10,681 |
| TOTAL | $8,918 | $9,905 | $10,898 | $10,028 | $12,568 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 296 | 354 | 411 | 468 | 525 |
| TOTAL | $296 | $354 | $411 | $468 | $525 |
| Total Liabilities | $9,214 | $10,258 | $11,309 | $10,497 | $13,093 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 43,596 | 42,447 | 41,218 | 41,252 | 41,252 |
| Common Shares | 43 | 41 | 41 | 41 | 41 |
| Retained earnings | -247,972 | -239,482 | -230,666 | -220,084 | -210,134 |
| TOTAL | $65,167 | $70,913 | $78,687 | $87,699 | $95,715 |
| Total Liabilities And Equity | $74,381 | $81,172 | $89,996 | $98,196 | $108,808 |